Medical Cannabis Fails to Show Benefit for Mental Health, Major Review Finds

Despite a surge in prescriptions, the largest ever review of medical cannabis trials has found no evidence it effectively treats anxiety, depression, or post-traumatic stress disorder (PTSD). The findings, published in The Lancet Psychiatry, raise questions about the widespread use of cannabis for these conditions and call for strengthened regulatory oversight.

Limited Evidence of Effectiveness

Researchers, led by Dr. Jack Wilson of the University of Sydney, analyzed 54 randomized controlled trials conducted since 1980, encompassing nearly 2,500 participants. The meta-analysis revealed a lack of demonstrable therapeutic effect for anxiety disorders, psychotic disorders, anorexia, PTSD, or opioid use disorder. Scientists noted a significant gap in high-quality research, with no double-blind randomized trials identified – the gold standard for scientific evidence.

Potential Harms Outweigh Benefits

Dr. Wilson cautioned that the use of cannabis, often containing high concentrations of tetrahydrocannabinol (THC), could be more harmful than beneficial. Potential risks include an increased risk of psychotic symptoms and cannabis use disorder. The study found that the risk of developing a cannabis-use disorder was comparable between those using cannabis medically and those using it recreationally. Researchers also observed that cannabis could worsen existing mental health symptoms.

Some Positive Findings

The review did identify some potential benefits in specific areas. Medicinal cannabis showed promise in reducing autistic traits in individuals with autism spectrum disorder, though the researchers emphasized the low certainty of this finding due to the limited number of studies and potential for bias. A moderate level of certainty suggested a reduction in insomnia symptoms and improved sleep duration. A combination of cannabidiol and THC appeared to reduce the severity of tics in patients with Tourette syndrome.

Concerns About Overprescription and Regulation

The study highlights a concerning trend: the increasing use of medical cannabis despite a lack of robust scientific evidence. Researchers suggest that regulatory oversight of medical cannabis prescriptions should be strengthened. Healthcare professionals often report feeling unprepared to address these treatments, potentially leading to both under- and over-prescription. Experts suggest a demand for improved training for medical professionals regarding the appropriate use of cannabinoids.

The Need for Further Research

Dr. Didier Jutras-Aswad, a specialist in the effects of cannabis at the University of Montreal Hospital Center, emphasized the limited amount of research available. “We barely have around sixty studies to get our teeth into,” he stated. The researchers advocate for a more nuanced public health message, minimizing both negative and positive attitudes associated with cannabis use to reduce expectancy and placebo effects. They also stress the importance of using tested and approved cannabis-based products.

Key Takeaways

• A major review found no evidence that medical cannabis is effective for anxiety, depression, or PTSD.
• The use of cannabis may carry risks, including psychosis and addiction.
• Some benefits were observed for autism, insomnia, and Tourette syndrome, but further research is needed.
• Regulatory oversight of medical cannabis prescriptions should be strengthened.
• More high-quality research is crucial to understand the true potential and risks of medical cannabis.